SAN FRANCISCO — Smart-ring company Oura is expanding clinical use of its Menopause Impact Scale, allowing users to share a structured report with healthcare providers through 10 partner organisations.
The company announced the integrations on 2 September. Its questionnaire asks about 22 symptoms across seven areas, including cognition, body image, sexual and vaginal symptoms, musculoskeletal pain, hot flushes, sleep maintenance and urinary symptoms.
Users rate how much each symptom has affected quality of life over the previous two weeks. The app converts responses into domain scores and an overall impact range, producing a downloadable report intended to support a clinical conversation.
Oura says more than 600,000 members have completed the assessment since it launched in May. That volume suggests substantial demand for a vocabulary that captures menopause beyond hot flushes alone.
A structured scale can help a patient remember symptoms, show change over time and make concerns harder to dismiss during a short appointment. It can also reveal clusters—sleep, pain and cognitive difficulty—that may require different forms of support.
The score is not a diagnosis. Similar symptoms can arise from thyroid disease, depression, medication effects, anaemia or other conditions. A high result should lead to careful assessment, not automatic hormone prescribing; a low score should not invalidate a patient’s concern.
Commercial integration raises equity questions. The Menopause Insights feature requires a supported Oura ring and active membership. Clinically useful assessment should also be available to women who cannot afford a device or do not want a private company collecting intimate health information.
Data governance must be explicit. Users need to know which answers and biometric signals enter a clinical record, which partner receives them, how long they are stored and whether de-identified information is used to develop products. Sharing a PDF by choice is different from continuous transmission by default.
The company should publish validation methods, demographic performance and evidence that use of the scale improves decisions or outcomes. Completion numbers demonstrate engagement, not clinical benefit.
Menopause care has long suffered from fragmented symptoms and rushed encounters. A well-designed report can restore some patient authority by translating lived experience into information a clinician can use.
The technology will earn trust only if it remains a tool rather than a toll gate: supporting the relationship between patient and professional, preserving consent and keeping essential care available without a ring.
Join the discussion